

Step Therapy Criteria
SAM 1-Tier SNP (2021) – Formulary ID: 21455 – Version 17
Effective Date: 12/01/2021
Last Updated: 11/01/2021

Abilify Mycite - (s)

Products Affected

- ABILIFY MYCITE TABLET 10 MG ORAL
- ABILIFY MYCITE TABLET 15 MG ORAL
- ABILIFY MYCITE TABLET 2 MG ORAL
- ABILIFY MYCITE TABLET 20 MG ORAL
- ABILIFY MYCITE TABLET 30 MG ORAL
- ABILIFY MYCITE TABLET 5 MG ORAL

Details

Criteria	Trial of generic aripiprazole. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

Formulary ID 21455 Version 17 Effective Date: 12/01/2021
UPPERCASE = Brand-name drug lowercase = generic drug

Antidepressants - (s)

Products Affected

- APLENZIN TABLET EXTENDED RELEASE 24 HOUR 174 MG ORAL
- APLENZIN TABLET EXTENDED RELEASE 24 HOUR 348 MG ORAL
- APLENZIN TABLET EXTENDED RELEASE 24 HOUR 522 MG ORAL
- DESVENLAFAXINE ER TABLET EXTENDED RELEASE 24 HOUR 100 MG ORAL
- DESVENLAFAXINE ER TABLET EXTENDED RELEASE 24 HOUR 50 MG ORAL
- EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

Details

Criteria	Trial of two of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine ER (ANDA generic), duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	---

Atypical Antipsychotics - (s)

Products Affected

- CAPLYTA CAPSULE 42 MG ORAL
- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- SAPHRIS TABLET SUBLINGUAL 10 MG SUBLINGUAL
- SAPHRIS TABLET SUBLINGUAL 2.5 MG SUBLINGUAL
- SAPHRIS TABLET SUBLINGUAL 5 MG SUBLINGUAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL

Details

Criteria	Trial of two of the following generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	---

BUPRENORPHINE/NALOXONE - s

Products Affected

- ZUBSOLV TABLET SUBLINGUAL 0.7-0.18 MG SUBLINGUAL
- ZUBSOLV TABLET SUBLINGUAL 1.4-0.36 MG SUBLINGUAL
- ZUBSOLV TABLET SUBLINGUAL 11.4-2.9 MG SUBLINGUAL
- ZUBSOLV TABLET SUBLINGUAL 2.9-0.71 MG SUBLINGUAL
- ZUBSOLV TABLET SUBLINGUAL 5.7-1.4 MG SUBLINGUAL
- ZUBSOLV TABLET SUBLINGUAL 8.6-2.1 MG SUBLINGUAL

Details

Criteria	Trial of generic buprenorphine/naloxone tablets and generic buprenorphine/naloxone film
-----------------	---

DPP4 INHIBITORS NON-PREFERRED - s

Products Affected

- KOMBIGLYZE XR TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG ORAL
- KOMBIGLYZE XR TABLET EXTENDED RELEASE 24 HOUR 5-1000 MG ORAL
- KOMBIGLYZE XR TABLET EXTENDED RELEASE 24 HOUR 5-500 MG ORAL

Details

Criteria	Trial of one of the following: Janumet, Janumet XR, Januvia, Jentadueto, Jentadueto XR, or Tradjenta
-----------------	--

FILGRASTIM - (s)

Products Affected

- GRANIX SOLUTION 300 MCG/ML SUBCUTANEOUS
- GRANIX SOLUTION 480 MCG/1.6ML SUBCUTANEOUS
- GRANIX SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML SUBCUTANEOUS
- GRANIX SOLUTION PREFILLED SYRINGE 480 MCG/0.8ML SUBCUTANEOUS
- NEUPOGEN SOLUTION 300 MCG/ML INJECTION
- NEUPOGEN SOLUTION 480 MCG/1.6ML INJECTION
- NEUPOGEN SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML INJECTION
- NEUPOGEN SOLUTION PREFILLED SYRINGE 480 MCG/0.8ML INJECTION

Details

Criteria	Trial or intolerance to Zarxio
----------	--------------------------------

INHALED CORTICOSTEROID - s

Products Affected

- QVAR AEROSOL SOLUTION 40 MCG/ACT INHALATION
- QVAR AEROSOL SOLUTION 80 MCG/ACT INHALATION
- QVAR REDIHALER AEROSOL BREATH ACTIVATED 40 MCG/ACT INHALATION
- QVAR REDIHALER AEROSOL BREATH ACTIVATED 80 MCG/ACT INHALATION

Details

Criteria	Trial of: Arnuity Ellipta and either Flovent Diskus or Flovent HFA
----------	--

Injectable GLP1 Agonists - s

Products Affected

- BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS
- BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS
- BYDUREON SUSPENSION RECONSTITUTED ER 2 MG SUBCUTANEOUS
- BYETTA 10 MCG PEN SOLUTION PEN-INJECTOR 10 MCG/0.04ML SUBCUTANEOUS
- BYETTA 5 MCG PEN SOLUTION PEN-INJECTOR 5 MCG/0.02ML SUBCUTANEOUS
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS
- OZEMPIC (1 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 3 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 4.5 MG/0.5ML SUBCUTANEOUS
- VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS

Details

Criteria	Trial of one of the following generic formulary metformin or metformin combinations: metformin, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Step requirements do not apply to members with type 2 diabetes and multiple cardiovascular risk factors or established cardiovascular disease.
-----------------	--

Leukotriene modifiers - (s)

Products Affected

- *zileuton er tablet extended release 12 hour 600 mg oral*

Details

Criteria	Trial of generic montelukast or generic zafirlukast
----------	---

NAMZARIC - s

Products Affected

- NAMZARIC CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 21-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 28-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 7-10 MG ORAL

Details

Details	
Criteria	Trial of generic memantine extended-release

PD agents -(s)

Products Affected

- NEUPRO PATCH 24 HOUR 1 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 2 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 3 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 4 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 8 MG/24HR TRANSDERMAL

Details

Criteria	Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole
-----------------	--

RELISTOR-(s)

Products Affected

- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS
- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS (0.6ML SYRINGE)
- RELISTOR SOLUTION 8 MG/0.4ML SUBCUTANEOUS
- RELISTOR TABLET 150 MG ORAL

Details

Criteria	Trial of Amitiza and lactulose
-----------------	--------------------------------

Index of Drugs

A

ABILIFY MYCITE TABLET 10 MG ORAL..	1
ABILIFY MYCITE TABLET 15 MG ORAL..	1
ABILIFY MYCITE TABLET 2 MG ORAL....	1
ABILIFY MYCITE TABLET 20 MG ORAL..	1
ABILIFY MYCITE TABLET 30 MG ORAL..	1
ABILIFY MYCITE TABLET 5 MG ORAL....	1
APLENZIN TABLET EXTENDED RELEASE 24 HOUR 174 MG ORAL.....	2
APLENZIN TABLET EXTENDED RELEASE 24 HOUR 348 MG ORAL.....	2
APLENZIN TABLET EXTENDED RELEASE 24 HOUR 522 MG ORAL.....	2

B

BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS.....	8
BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS.....	8
BYDUREON SUSPENSION RECONSTITUTED ER 2 MG SUBCUTANEOUS.....	8
BYETTA 10 MCG PEN SOLUTION PEN- INJECTOR 10 MCG/0.04ML SUBCUTANEOUS.....	8
BYETTA 5 MCG PEN SOLUTION PEN- INJECTOR 5 MCG/0.02ML SUBCUTANEOUS.....	8

C

CAPLYTA CAPSULE 42 MG ORAL.....	3
---------------------------------	---

D

DESVENLAFAXINE ER TABLET EXTENDED RELEASE 24 HOUR 100 MG ORAL.....	2
DESVENLAFAXINE ER TABLET EXTENDED RELEASE 24 HOUR 50 MG ORAL.....	2

E

EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL	2
EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL	2
EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL	2

F

FANAPT TABLET 1 MG ORAL.....	3
FANAPT TABLET 10 MG ORAL.....	3
FANAPT TABLET 12 MG ORAL.....	3

FANAPT TABLET 2 MG ORAL.....	3
FANAPT TABLET 4 MG ORAL.....	3
FANAPT TABLET 6 MG ORAL.....	3
FANAPT TABLET 8 MG ORAL.....	3
FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL.....	3
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL	2
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL	2
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL	2
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL	2
FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL	2

G

GRANIX SOLUTION 300 MCG/ML SUBCUTANEOUS.....	6
GRANIX SOLUTION 480 MCG/1.6ML SUBCUTANEOUS.....	6
GRANIX SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML SUBCUTANEOUS.....	6
GRANIX SOLUTION PREFILLED SYRINGE 480 MCG/0.8ML SUBCUTANEOUS.....	6

K

KOMBIGLYZE XR TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG ORAL	5
KOMBIGLYZE XR TABLET EXTENDED RELEASE 24 HOUR 5-1000 MG ORAL	5
KOMBIGLYZE XR TABLET EXTENDED RELEASE 24 HOUR 5-500 MG ORAL ..	5

N

NAMZARIC CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG ORAL.....	10
NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG ORAL	10
NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 21-10 MG ORAL	10
NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 28-10 MG ORAL	10

Formulary ID 21455 Version 17 Effective Date: 12/01/2021

UPPERCASE = Brand-name drug lowercase = generic drug

NAMZARIC CAPSULE EXTENDED
 RELEASE 24 HOUR 7-10 MG ORAL.. 10
 NEUPOGEN SOLUTION 300 MCG/ML
 INJECTION..... 6
 NEUPOGEN SOLUTION 480 MCG/1.6ML
 INJECTION..... 6
 NEUPOGEN SOLUTION PREFILLED
 SYRINGE 300 MCG/0.5ML INJECTION 6
 NEUPOGEN SOLUTION PREFILLED
 SYRINGE 480 MCG/0.8ML INJECTION 6
 NEUPRO PATCH 24 HOUR 1 MG/24HR
 TRANSDERMAL 11
 NEUPRO PATCH 24 HOUR 2 MG/24HR
 TRANSDERMAL 11
 NEUPRO PATCH 24 HOUR 3 MG/24HR
 TRANSDERMAL 11
 NEUPRO PATCH 24 HOUR 4 MG/24HR
 TRANSDERMAL 11
 NEUPRO PATCH 24 HOUR 6 MG/24HR
 TRANSDERMAL 11
 NEUPRO PATCH 24 HOUR 8 MG/24HR
 TRANSDERMAL 11
O
 OZEMPIC (0.25 OR 0.5 MG/DOSE)
 SOLUTION PEN-INJECTOR 2
 MG/1.5ML SUBCUTANEOUS..... 8
 OZEMPIC (1 MG/DOSE) SOLUTION PEN-
 INJECTOR 2 MG/1.5ML
 SUBCUTANEOUS..... 8
Q
 QVAR AEROSOL SOLUTION 40 MCG/ACT
 INHALATION..... 7
 QVAR AEROSOL SOLUTION 80 MCG/ACT
 INHALATION..... 7
 QVAR REDIHALER AEROSOL BREATH
 ACTIVATED 40 MCG/ACT INHALATION
 7
 QVAR REDIHALER AEROSOL BREATH
 ACTIVATED 80 MCG/ACT INHALATION
 7
R
 RELISTOR SOLUTION 12 MG/0.6ML
 SUBCUTANEOUS..... 12
 RELISTOR SOLUTION 12 MG/0.6ML
 SUBCUTANEOUS (0.6ML SYRINGE) 12

RELISTOR SOLUTION 8 MG/0.4ML
 SUBCUTANEOUS..... 12
 RELISTOR TABLET 150 MG ORAL..... 12
S
 SAPHRIS TABLET SUBLINGUAL 10 MG
 SUBLINGUAL..... 3
 SAPHRIS TABLET SUBLINGUAL 2.5 MG
 SUBLINGUAL..... 3
 SAPHRIS TABLET SUBLINGUAL 5 MG
 SUBLINGUAL..... 3
T
 TRULICITY SOLUTION PEN-INJECTOR
 0.75 MG/0.5ML SUBCUTANEOUS 8
 TRULICITY SOLUTION PEN-INJECTOR
 1.5 MG/0.5ML SUBCUTANEOUS 8
 TRULICITY SOLUTION PEN-INJECTOR 3
 MG/0.5ML SUBCUTANEOUS..... 8
 TRULICITY SOLUTION PEN-INJECTOR
 4.5 MG/0.5ML SUBCUTANEOUS 8
V
 VICTOZA SOLUTION PEN-INJECTOR 18
 MG/3ML SUBCUTANEOUS..... 8
 VRAYLAR CAPSULE 1.5 MG ORAL..... 3
 VRAYLAR CAPSULE 3 MG ORAL..... 3
 VRAYLAR CAPSULE 4.5 MG ORAL..... 3
 VRAYLAR CAPSULE 6 MG ORAL..... 3
 VRAYLAR CAPSULE THERAPY PACK 1.5
 & 3 MG ORAL..... 3
Z
 zileuton er tablet extended release 12 hour
 600 mg oral 9
 ZUBSOLV TABLET SUBLINGUAL 0.7-0.18
 MG SUBLINGUAL 4
 ZUBSOLV TABLET SUBLINGUAL 1.4-0.36
 MG SUBLINGUAL 4
 ZUBSOLV TABLET SUBLINGUAL 11.4-2.9
 MG SUBLINGUAL 4
 ZUBSOLV TABLET SUBLINGUAL 2.9-0.71
 MG SUBLINGUAL 4
 ZUBSOLV TABLET SUBLINGUAL 5.7-1.4
 MG SUBLINGUAL 4
 ZUBSOLV TABLET SUBLINGUAL 8.6-2.1
 MG SUBLINGUAL 4

Formulary ID 21455 Version 17 Effective Date: 12/01/2021
UPPERCASE = Brand-name drug lowercase = generic drug